AI empowers regional drug R&D. The UAE team of InSilico Intelligence nominated the first preclinical candidate drug.

English Silicon Intelligence has announced that ISM0387 has been officially nominated as a preclinical candidate drug. This molecule was discovered by English Silicon Intelligence's team in the UAE using the company's proprietary Pharma.AI platform, and the early drug discovery process from molecular design to optimization has been completed within the UAE in less than 12 months. ISM0387 is a novel MTA synergistic PRMT5 inhibitor designed with AI empowerment, showing good in vitro activity and selectivity in preclinical studies, optimized blood-brain barrier penetration, strong therapeutic effects in disease models, and a clear dose-dependent trend. With its new molecular structure and excellent central nervous system penetration capability, ISM0387 offers a promising potential new treatment option for patients with glioblastoma.